Skip to main content

Table 2 Multivariate Cox proportional hazards analyses of clinicopathological variables and CMTC as prognostic indicators in the 3,963 overall breast cancers

From: Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populations

Variables

Hazard ratio

95%CI

P value

ER (+) versus (-)

1.10

0.89 to 1.36

4.00E-01

Non-HER2/TN versus HER2+/TN

1.26

1.03 to 1.54

2.20E-02

Age <50 versus > = 50

0.85

0.74 to 0.96

1.10E-02

Size < =2 cm versus >2 cm

1.78

1.56 to 2.02

0.00E + 00

LN (-) versus (+)

0.68

0.60 to 0.77

8.20E-10

Grade1 versus 2

1.50

1.17 to 1.91

1.30E-03

Grade1 versus 3

1.40

1.09 to 1.81

9.80E-03

CMTC-1 versus 2

2.06

1.73 to 2.46

1.00E-15

CMTC-1 versus 3

2.01

1.62 to 2.50

3.30E-10

  1. CI, confidence interval; CMTC, ClinicoMolecular Triad Classification; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LN, lymph node status; TN, triple-negative.